Abstract：Objective: To detect the expression of neural cell adhesion molecule (NCAM), tyrosine kinase receptor B (TrkB) and brain-derived neurotrophic factor (BDNF) in patients with schizophrenia, and to explore the correlation between their expression levels and clinical symptoms. Methods: Seventy schizophrenic patients from August 2018 to August 2020 were selected as the schizophrenia group, at the same time, 70 healthy people who had routine physical examination in the physical examination center of our hospital were selected as the control group. Enzyme linked immunosorbent assay (ELISA) was used to detect the expression levels of NCAM, TrkB and BDNF in serum. The positive and negative syndrome scale (PANSS) was used to evaluate the clinical symptoms. Pearson method was used to analyze the correlation between serum NCAM, TrkB, BDNF expression levels and PANSS score; and Logistic regression analysis was used to analyze the related factors of schizophrenia; receiver operating characteristic curve (ROC) was used to evaluate the diagnostic value of serum NCAM, TrkB and BDNF levels in patients with schizophrenia. Results: The serum levels of NCAM, TrkB and BDNF in schizophrenia group were significantly lower than those in control group (P<0.05). The total score of PANSS was (78.67 ± 7.51), and the positive symptom score was (29.38 ± 4.25), and the negative symptom score was (26.72 ± 5.96), and the general pathological symptom score was (22.57 ± 6.20). Serum NCAM, TrkB and BDNF levels were negatively correlated with total score and positive symptom score of PANSS (P<0.05). The low expression of NCAM, TrkB and BDNF was an independent risk factor of schizophrenia (P<0.05). The AUC of serum NCAM, TrkB and BDNF in the diagnosis of schizophrenia was 0.863, 0.788 and 0.885 respectively, and the cut-off value was 47.773 μg/mL, 42.727 ng/mL and 29.487 pg/mL, respectively, the corresponding sensitivity was 67.1%, 65.7%, 84.3%, and the specificity was 87.1%, 78.6% and 74.3%, respectively. Conclusion: The expression levels of NCAM, TrkB and BDNF in the serum of schizophrenics are significantly reduced, and are negatively related to the severity of clinical symptoms, and may participate in the occurrence and development of schizophrenia.
[1] 彭兴,马辛,任艳萍,等.精神分裂症患者语义距离与认知功能的相关性研究[J].中华行为医学与脑科学杂志,2020,29(9):797~801. [2] 刘亚平,唐小伟,冯旭薇.精神分裂症患者血清降钙素原表达水平与BPRS量表值及症状的关系分析[J].现代检验医学杂志,2020,35(2):122~124. [3] 于春磊,唐宋琪,李晓明,等.莪术对血瘀证和正常孕大鼠血液及子代脑组织神经黏附分子基因表达的影响[J].中医学报,2018,33(10):1966~1969. [4] Betti L,Palego L,Unti E,et al.Brain-derived neurotrophic factor (BDNF) and serotonin transporter (SERT) in platelets of patients with mild huntington's disease:relationships with social cognition symptoms[J].Arch Ital Biol,2018,156(1~2):27~39. [5] 师佳,戴丹,李洋洋,等.脑卒中后抑郁大鼠海马小胶质细胞脑源性神经营养因子及酪氨酸激酶受体B蛋白的表达[J].中华老年心脑血管病杂志,2018,20(1):89~93. [6] 中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184~188. [7] Gusev A,Mancuso N,Won H,et al.Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights[J].Nat Genet,2018,50(4):538~548. [8] Jin H,Mosweu I.The societal cost of schizophrenia:a systematic review[J].Pharmaco Economics,2017,35(1):25~42. [9] Frank F,Bezold V,Bork K,et al.Advanced glycation endproducts and polysialylation affect the turnover of the neural cell adhesion molecule (NCAM) and the receptor for advanced glycation endproducts (RAGE)[J].Biol Chem,2018,400(2):219~226. [10] An HM,Zhou LP,Yu Y,et al.Serum NCAM levels and cognitive deficits in first episode schizophrenia patients versus health controls[J].Schizophr Res,2018,192(1):457~458. [11] Lima Giacobbo B,Doorduin J,Klein HC,et al.Brain-derived neurotrophic factor in brain disorders:focus on neuroinflammation[J].Mol Neurobiol,2019,56(5):3295~3312. [12] 张欣,孟杰,吕华,等.首发精神分裂症患者血清miR-103a和BDNF的表达及临床意义[J].山西医科大学学报,2019,50(8):1174~1178. [13] 王红丽,李继涛,苏允爱,等.BDNF-TrkB信号系统在精神分裂症发病及治疗中的作用[J].国际精神病学杂志,2017,44(2):12~15 [14] 赵孟,王玉婷,彭安林,等.半乳糖凝集素-3在大鼠精神分裂症发病机制中的作用[J].中国神经精神疾病杂志,2019,45(1):32~36.
2021, Vol. 27 
冀公网安备13080202000677号